Drug for treating chronic pelvic inflammatory disease

A technology of chronic pelvic inflammatory disease and pharmaceuticals, which is applied in the direction of diseases, drug combinations, and medical formulas, can solve problems such as stubborn and difficult to heal, protracted course of disease, and incomplete treatment, and achieve good safety and clear curative effect

CN104623216AInactive Publication Date: 2015-05-20蒋梅
3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2015-05-20
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

The invention relates to a drug for treating chronic pelvic inflammatory disease. The drug is prepared from the following matters in weight ratio: torenia fournieri, manchurian catalpa bark, schisandra propinqua, green fig root, plum blossom, cissus pteroclada hayata, folium ilicis purpurea, java bishopwood root-bark branchlet and leaf, parmelia tinctorum despr, hypericum attenuatum choisy, reineckia carnea, sanicle, lespedeza cuneata G. Don, Pleurospermum hookeri C.B.Clarde var.thomsonii C.B.Clarke, japanese xylosma bark, perny false fairybells rhizome, lombardy poplar, Indian epimeredi herb, wild spikenard stem and leaf, lychnis coronate, dendrobium candidum and ginseng fruit. All components of the drug for treating chronic pelvic inflammatory disease provided by the invention are natural materials, so that the safety is better, the curative effect is exact, and the drug is suitable for large-scale clinical promotion.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention is a divisional application of a patent with the application number 2013105902549, the filing date being November 20, 2013, and the title of the invention being "a medicament for treating chronic pelvic inflammatory disease". technical field

[0002] The invention relates to the field of medicaments, in particular to a medicament for treating chronic pelvic inflammatory disease. Background technique

[0003] Modern medicine believes that chronic pelvic inflammatory disease is mostly due to incomplete treatment in the acute phase, or the patient is weak, the course of the disease is protracted, and there is also aseptic inflammation. Long-term inflammation stimulates fibrous tissue hyperplasia and forms adhesions around the pelvic organs. Difficult to heal. The present invention has been accomplished on this basis. Contents of the invention

[0004] The object of the present invention is to provide a medicament for treating chronic pelvic infla...

Examples

Embodiment

[0012] Embodiment Decoction of the present invention

[0013] Weigh 6 grams of blue pig ear, 8 grams of catalpa bark, 5 grams of Manshanxiang, 3 grams of banyan root, 9 grams of plum blossom, 5 grams of Sifang rattan, 8 grams of Sijiqing, 3 grams of autumn maple, 2 grams of white stone flower, 3 grams of whip, 8 grams of auspicious grass, 3 grams of bean vegetables, 2 grams of Yeguanmen, 5 grams of Zaiguo, 5 grams of oak bark, 2 grams of yellow-footed chicken, 7 grams of Zhutianyang, 6 grams of Luomayi, 3 grams of snake hundred seeds, Add 5 grams of Xialuo, 6 grams of black knot grass and 8 grams of head seven, add 6000 milliliters of water, heat in a flask equipped with a condenser tube at 80 ° C for 6 hours, filter, and the filtrate is the decoction of the present invention .

experiment example

[0015] Diagnostic criteria

[0016] According to the content of chronic pelvic inflammatory disease in the "Guiding Principles of Clinical Research of New Chinese Medicine Drugs" formulated by the Ministry of Health in 1993 in the "Clinical Guiding Principles of New Chinese Medicine Drugs for Inflammation of the Female Reproductive System", the diagnostic criteria were formulated: all cases were treated with waist and abdominal pain; Accompanied by yellow-red leucorrhea, no less than 20 cases with leucorrhea cleanliness III or above; accompanied by irregular menstruation, such as heavy menstrual flow, and no less than 20 cases with prolonged menstrual time.

[0017] Exclusion criteria: ① Those who took less than 1 course of treatment for some reason; ② Those who discontinued treatment due to serious adverse reactions (included in adverse reaction statistics).

[0018] Select 50 patients who meet the above diagnostic criteria, including 20 cases aged 20-30 years old, 20 cases a...